Background: Clinical significance of delayed-onset neutropenia (DON) after autologous hematopoietic stem-cell transplantation (ASCT) has not been well described. We conducted a retrospective cohort study to examine risk factors and clinical impact of DON.
introduction
Rituximab is a chimeric monoclonal anti-CD20 antibody containing human immunoglobulin G1 kappa constant regions with murine variable regions [1] . It displays significant therapeutic activity for CD20-positive B-cell non-Hodgkin lymphoma (B-NHL) both as a single agent and in combination with cytotoxic chemotherapy [2] [3] [4] [5] . Rituximab can also be used before and after autologous hematopoietic stem-cell transplantation (ASCT) showing powerful antitumor effects and pure graft collection, without additive severe hematological toxicity and delaying time to engraftment after ASCT [6] [7] [8] [9] [10] .
Delayed-onset neutropenia (DON) has been recently reported as a late complication of rituximab usage [8, [11] [12] [13] [14] [15] . Reversible rituximab-related DON tends to occur within 6 months after the last infusion of rituximab. Although some study showed that DON occurred more often in patients receiving rituximab in combination with intensive-or highdose therapy [15] , we sometimes had an experience of DON developing after ASCT even in the patients without rituximab exposure. To what extent rituximab contributes to the occurrence of DON is yet elucidated in the situation of rituximab usage for the patients undergoing ASCT.
Impact of DON is relatively subclinical and little clinical importance after standard chemotherapy [11, 15] . Lemieux et al. [14] reported that its occurrence with the immunosuppressive condition such as post-transplantation might predispose some patients to serious but not life-threatening infectious complication; its clinical impact after ASCT is, however, not well known from large series. We conducted a retrospective study to analyze the clinical significance and risk factors of DON in patients with B-NHL receiving induction chemotherapy with or without rituximab followed by ASCT. design and methods
study group
This was an institutional review board-approved retrospective cohort study. Medical records of the consecutive B-NHL treated with high-dose therapy followed by ASCT were reviewed in our institute from 20 June 1991 to 31 January 2007, and a total of 111 patients were selected. The patients who received prior rituximab monotherapy or combination chemotherapy were included, and those were excluded if they had undergone prior transplantation. The patients were also excluded if they had engraftment failure after ASCT, had progressive disease or had received other chemotherapy except rituximab monotherapy within 30 days after ASCT.
study definition
Clinical significance was defined in this study as occurrence of documented infectious events after ASCT. Infectious events were reviewed in all patients between 30 days and 1.5 years or last follow-up after ASCT regardless of DON episodes. Nine factors were included in infectious events: Varicellazoster virus (VZV) infection, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) antigenemia or infection, fever (>38.0°C), upper respiratory infection, pneumonia (excluding interstitial lung diseases), gastroenteritis, urinary tract infections, and other infectious events. Other infectious events represented local bacterial infections.
DON was defined as absolute neutrophil count (ANC) <1.0 · 10 9 /l at any point from 30 days after ASCT to last follow-up without apparent causes of neutropenia after neutrophil engraftment. Patients were counted as censored events if they had apparent causes of neutropenia such as disease progression, drug-related toxic effects or secondary hematologic malignancies, and those were also counted as censored events if they had further chemotherapy after ASCT. Patients were not counted as censored events who had neutropenia followed by infectious events or had the ambiguous onset or who were treated after ASCT with rituximab monotherapy or local radiation therapy for residual diseases. Severity of DON, hematologic toxic effects, and infectious events were evaluated according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 2. Engraftment was defined as the first of two consecutive days on which the patient's ANC was ‡0.5 · 10 9 /l and unsupported platelet counts were ‡20 · 10 9 /l within 30 days after ASCT.
statistical considerations
Incidence of DON was analyzed by cumulative incidence method. Risk factors of DON were evaluated for 16 factors including rituximab usage, age (£60 or >60 years), sex, histology (aggressive or indolent), number of extra nodal sites (£1 or ‡2), performance status (£1 or ‡2), existence of B symptoms (presence or absence of night sweat, >10% weight loss over 6 months, or recurrent fever >38.3°C), the level of lactate dehydrogenase (normal or elevated), existence of bone marrow involvement, existence of bulky lesion (present or absent, largest diameter of the disease ‡10 cm), prior local radiation therapy, number of prior chemotherapy regimens (£2 or ‡3), pretransplantation setting (up front or relapse/refractory disease), status at ASCT (complete remission or partial remission), CD34-selected ASCT, and types of conditioning regimens [total body irradiation (TBI)-containing regimens or non-TBI regimens]. Bias due to indication of rituximab treatment was considered by application of propensity score [16] . Risk factors for DON occurrence were explored by Cox proportional hazards model applying stepwise method (P value for removal = 0.10 and that for inclusion = 0.05). Finally, we applied bootstrap resampling method for validation of our analyses (repeating 10 000 times with 108 sampling from original cohort). All the analyses were stratified by quartile of propensity score. Cumulative incidence of infectious events was estimated by KaplanMeier method in this study on the grounds that substituting Kaplan-Meier method evaluating as time-varying covariate for cumulative incidence method produced the same results. Potential risk factors associated with infectious events were analyzed, evaluating as time-varying covariate, for 17 factors including DON in addition to the aforementioned 16 factors. Univariable analyses for infectious events were carried out using the cut-off value of 0.15, and factors associated with significance in univariable analyses were subjected to multivariable analyses (the cut-off value of 0.05). These analyses were carried out with the use of STATA software (version 10; StataCorp LP, College Station, TX).
results

study group
Two patients were excluded because of early disease progression. A patient given rituximab 2.3 years before ASCT was also excluded. One patient who received high-dose therapy but not stem-cell transplantation was included, and all the other patients were eligible. Finally, we proved analyses for a total of 108 patients. Patient characteristics were shown in Table 1 . Forty-nine patients had diffuse large B-cell lymphoma, 35 follicular lymphoma, 20 mantle cell lymphoma and 4 other B-NHL. Fifteen (14%) patients had prior rituximab exposure before pretransplantation induction chemotherapy. Seventeen patients who received CD34-selected stem-cell transplantation were all rituximab naive. Two patients had a previous history of fludarabine or cladribine administration, and no patient had a history of alemtuzumab injection. The median number of prior treatment regimens was 2. Fifty-six (52%) patients received rituximab in combination with pretransplantation induction chemotherapy. The patients who had rituximab usage received the last rituximab infusion within 3 months before transplantation (median 45 days, range . No patients had rituximab given during conditioning therapy, and two patients received rituximab monotherapy after ASCT.
Granulocyte colony-stimulating factor (G-CSF) was administered in all patients until neutrophil engraftment after ASCT, and the median time to engraftment of ANC ( ‡0.5 · 10 9 /l) was 10 days (range 7-17 days).
incidence and clinical impact of DON Cumulative incidence of DON was 50% [95% confidence interval (CI) 40% to 59%] in all patients at 1 year, 66% (95% CI 52% to 77%) with rituximab usage group, and 33% (95% CI 21% to 45%) without rituximab group. DON occurred more often in the group with rituximab usage (P = 0.003, log-rank test) ( Figure 1 ). The two patients who had a previous history of fludarabine or cladribine administration experienced DON, one of which was a rituximab-naive patient. The median days of first onset of DON was 71 (range 31-399) after ASCT. The median number of DON occurrence was 2 (range 1-10). The median interval of first onset days of DON to second was 36 days (range 4-320 days). The median value of nadir neutrophil count during DON was 0.446 · 10 9 /l (range 0.009-0.968 · 10 9 / l) at a median of 96 days (range 32-686 days) after ASCT, and grade 4 neutropenia (neutrophil counts <0.5 · 10 9 /l) was observed in 53% of patients (Figure 2a) . Fifteen (27%) of 55 DON patients experienced bicytopenia (neutropenia and grade 3 or 4 thrombocytopenia or anemia), 6 of which had pancytopenia (neutropenia, grade 3 or 4 thrombocytopenia and anemia). Most patients had grade 3 thrombocytopenia or anemia. The rituximab usage group had a trend of the later onset of first and nadir days of DON (Figure 2b ). The median duration of the DON period could not be defined in this study because most patients received outpatient care and timing of their next visit after the occurrence of DON was arbitrary by each physician's decision. During DON, 14 samples (25%) of bone marrow were obtained; 8 were hypocellular marrow and 6 ASCT, autologous hematopoietic stem-cell transplantation; PBSCH, peripheral blood stem cell harvest; TBI, total body irradiation; PB, peripheral blood stem cells; BM, bone marrow.
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were normocellular. Some samples showed maturation arrest. B lymphocytes were depleted in about a half of the patients. An excess of T-large granular lymphocyte in bone marrow, which is indicated as a possible pathogenetic mechanisms of DON [17] , was not confirmed in this study. Eleven patients (20%) received G-CSF during the period of DON. In all period, a total of 117 events were documented (Table 2) . Most infectious events (62%) were observed within a half-year, and only eight events were documented after 1.5 years. Of the 117 events, 24 infectious events were documented during the period of DON. All events were grade1-3 (most of them were grade 1-2), and early appropriate care brought to the patients rapid improvement. Neither life-threatening nor toxic death was observed. Cumulative incidence of total infectious events at 1 year was 60% (95% CI 51% to 70%), 75% (95% CI 63% to 85%), and 42% (95% CI 29% to 58%) in all patients, with, and without DON group, respectively; VZV infection was 24% (95% CI 17% to 34%), 31% (95% CI 21% to 45%), and 17% (95% CI 9% to 31%) in all patients, with, and without DON group, respectively; and upper respiratory infection was 14% (95% CI 9% to 23%), 23% (95% CI 14% to 36%), and 4% (95% CI 1.1% to 17%) in all patients, with, and without DON group, respectively ( Figure 3 ). There had been no overt evidence of other viral-related complications such as progressive multifocal leukoencephalopathy (PML) as recently reported [18] .
statistical considerations for risk factors of DON and infectious events
By stepwise method, selected factors for final validation model were rituximab usage, existence of bulky lesion, sex, pretransplantation setting, and histology. In the validation, usage of rituximab [odds ratio (OR) = 4.5, 95% CI 1.3-15.8, P = 0.020] and female sex (OR = 4.7, 95% CI 2.4-9.4, P < 0.001) were identified as a risk factor for DON (Table 3 ). Other factors failed to demonstrate significant impact on DON.
In univariable analyses, DON (P = 0.001) and age (P = 0.072) were identified as risk factors for total infectious events; DON (P = 0.033), sex (P = 0.026), and status at ASCT (P = 0.076) for VZV infection; age (P = 0.037), pretransplantation setting (P = 0.103), and number of prior chemotherapy regimens (P = 0.053) for HSV infection; pretransplantation setting (P = 0.128) and status at ASCT (P = 0.145) for CMV; age >60 years (P = 0.061), pretransplantation setting (P = 0.126), number of prior chemotherapy regimens (P = 0.086), and status at ASCT (P = 0.100) for fever; DON (P = 0.016) for upper respiratory infection; age (P = 0.095) for pneumonia; and DON (P = 0.108), rituximab usage (P = 0.087), number of extra nodal sites (P = 0.015), and original article Annals of Oncology TBI (P = 0.001) for gastroenteritis. Multivariable analyses identified that DON was an independent risk factor for total infectious events [hazard ratio (HR) 2.3, 95% CI 1.3-3.8, P = 0.002] and TBI usage for gastroenteritis (HR 4.6, 95% CI 1.4-15.3, P = 0.013). Table 4 showed impact of DON for infectious events. DON did not affect both progression-free and overall survival (data not shown).
In subset analyses, we limited analyses to the groups of the patients receiving ASCT before (n = 26) and after (n = 82) 1999, the patients receiving CD34-selected stem-cells (n = 17) or not (n = 91), and the patients with indolent (n = 37) or aggressive lymphoma (n = 71). The groups receiving ASCT after 1999, receiving CD34-unselected stem-cells, and with indolent lymphoma demonstrated frequent occurrence of DON in rituximab usage group (log-rank test, P < 0.01). These groups and aggressive lymphoma showed significant impact of DON on total infectious events. The groups receiving ASCT before 1999 and CD34-selected stem-cells failed to demonstrate clinical impact of DON.
discussion
In the earlier studies of single-agent rituximab therapy in patients with relapsed low-grade B-NHL [2, 3] , neutropenia was observed in 5-8% of patients between the completion of therapy and the first year of follow-up, and these neutropenia were generally transient and self-limited. Thereafter, development of neutropenia with a different pattern of onset has been reported [4, [11] [12] [13] [14] . Nitta et al. [15] revealed that rituximab combined with chemotherapy as a primary treatment showed a 25% incidence of grade 3 neutropenia, and most patients experienced a single episode of DON. Rituximab treatment in combination with intensive or ASCT produced higher frequency of DON [6, 8, [13] [14] [15] . Moreover, DON was also documented in the patients with autoimmune diseases receiving rituximab treatment [19, 20] , and the patients receiving standard chemotherapy without rituximab did not experience DON [15] . Current study also showed high incidence of DON (50%), and 61% of patients experienced ‡ 2 episodes. Rituximab combined with myelotoxic chemotherapy could produce higher frequency of DON (66%); however, the non-rituximab patients experienced DON of a 33% incidence in our study. These results implied that DON could not be explained as a simple homogenous phenomenon.
Patients who received rituximab showed B lymphocyte depletion, and it causes significant changes of the T lymphocytes compartment [21] or a decrease in the absolute number of T lymphocytes [22] . Lymphocytes and immune system showed slow recovery after rituximab usage. Median recovery time for CD4+ T-cell counts, B-cell counts, and (c) Figure 3 . Cumulative incidence of infectious events. Cumulative incidence of total infectious events at 1 year was 75% and 42% with and without DON group, respectively (a); VZV infection was 31% and 17% (b); and upper respiratory infection was 23% and 4% (c). *Log-rank test. DON, delayed-onset neutropenia; VZV, Varicella-zoster virus.
Annals of Oncology original article
immunoglobulins was a year or longer in patients receiving peri-transplantation rituximab [23] . Rituximab is thought to inhibit B lymphocyte survival and proliferation through negative regulation of canonical signaling pathways involving Akt, extracellular signal-regulated kinase (ERK), and mammalian target of rapamycin (mTOR) [24, 25] . The etiology of DON is, however, not yet clearly understood. Some factors indicated possible pathogenetic mechanisms of DON such as anti-neutrophil antibody [11, 12] , T-large granular lymphocyte [17] , soluble Fas-ligand [17] , perturbation of stromal-derived factor 1 and granulopoiesis homeostasis during B-cell recovery [26] , and an excessive B-cell depletion and recovery which were assessable by the serum level of BAFF (B-cell activation factor belonging to the tumor necrosis factor family) [27] . In this study, an excess of T-large granular lymphocyte in bone marrow was not confirmed, and all patients did not show hypoplastic marrow as previously described [28] . Considering that patients without rituximab experienced DON, rituximab usage seems not to be the sole cause. Moreover, the observation that the rituximab group had a trend of the later onset and nadir days of DON may indicate the different mechanism of DON between two groups. Further investigation is needed to clarify etiology and pathogenesis of DON.
Infectious episodes associated with DON were generally selflimited without serious infectious complication after standard chemotherapy [2-4, 11, 15] ; DON, however, posed for some patients serious but not life-threatening infectious complications in the setting after ASCT [14] . In the current study, we investigated whether the clinical course was affected by the onset of DON, and detailed the infectious events not only during the period with DON, but also in the period without DON. Although DON was associated with the occurrence of infectious events after ASCT, most events were generally mild to moderate, even in the period with DON, owing to early appropriate treatment. Considering slow recovery of lymphocytes and immune system after peritransplant rituximab usage [23] , early appropriate care would be necessary to prevent infectious events from developing to severe status.
Rituximab usage itself was not identified as an independent risk factor for infectious events and many patients receiving rituximab, if experiencing DON, did not show serious viral infections in our cohort; however, severe and life-threatening viral complications have recently drawn a lot of attention on rituximab therapy. Carson et al. [18] reported 57 cases of PML after rituximab therapy in human immunodeficiency virusnegative patients from the Research on Adverse Drug Events and Reports project. PML is caused by JC polyoma virus, and the pathophysiology of rituximab-associated PML is yet fully understood, particularly with respect to the role of rituximab. It is a rare, but serious and usually fetal central nervous system infection (the case-fatality rate; 90%). Food and Drug Administration (FDA) approved the package insert of rituximab to include information regarding the increased risks of PML and other viral related complications such as hepatitis B (HB) and hepatitis C reactivation, VZV, HSV, cytomegalovirus, and parvovirus B19. More recently, FDA has declined to extend rituximab's licensed indication to include first-line therapy for rheumatoid arthritis, because of concerns related to PML. PML was not documented in our study and there is no report on association of DON with PML so far. How careful was the observation of these individuals is not yet clearly defined. Moreover, for many viral infections, anti-viral therapy may not be helpful, nor may early intervention always be clinically useful. Since rituximab is now increasingly administered for nonmalignant illnesses as well [29, 30] , risk-benefit considerations are important in the application of rituximab.
There were some episodes found besides our analyses. Nine HB carriers were documented. Of these, HB virus reactivation was observed in one patient, who was positive for HB envelope antigen and had received therapeutic antivirus agent before induction chemotherapy. We could not conclude definite prevalence of HB reactivation and its association with DON in this study, because most patients especially in the earlier cohort had not been tested for HB surface antibody or HB core antibody. Two patients were found to develop auto-immune diseases after ASCT [hypothyroidism and immune thrombocytopenic purpura, (ITP)]. The patient with hypothyroidism received rituximab and experienced DON; on the other hand, the patient with ITP was not affected with both. Considering rituximab usage or T-cell depletion has showed a clinically rational option to hypothyroidism [30] and its disease original article Annals of Oncology prevalence was the same as a population based study, we could not make definite conclusion that the auto-immune disease was acquired through rituximab usage or occurrence of DON.
In conclusion, this study demonstrated that rituximab usage for the patients receiving ASCT was an independent risk factor of DON considering bias due to indication of rituximab treatment, and DON correlated with increased occurrence of infectious events after ASCT. Careful follow-up would be needed for the patients having an experience of DON after ASCT. The interpretation of this result may not always be comparable because of this retrospective study design. Further studies should be reported from other settings as well as some case-control type epidemiologic studies. 
